DNMT3A and acute myeloid leukemia: Meanwhile, data in the TCGA database also showed that high BRAF expression could identify AML patients with worse outcome regardless of TET2 and DNMT3A mutations (Additional file 1: Fig. S1A–C), and AML patients with both high BRAF expression and these mutations were more likely to distributed in older population (Additional file 1: Fig. S1D–E).